Neoadjuvant and Adjuvant Immunotherapy in Non-Small Cell Lung Cancer—Clinical Trials Experience

SIMPLE SUMMARY: Surgical resection remains the gold standard of early-stage non-small cell lung cancer (NSCLC) treatment. However, only a minority of resected patients remain recurrence-free at 5 years. Systemic treatment with cisplatin-based chemotherapy after surgical resection has been shown to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chmielewska, Izabela, Stencel, Katarzyna, Kalinka, Ewa, Ramlau, Rodryg, Krawczyk, Paweł
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534159/
https://www.ncbi.nlm.nih.gov/pubmed/34680195
http://dx.doi.org/10.3390/cancers13205048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534159/
https://www.ncbi.nlm.nih.gov/pubmed/34680195
http://dx.doi.org/10.3390/cancers13205048

Ejemplares similares